|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content.
|
28445515 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These cellular results were confirmed using tumor xenografts in mice, as DSG3 silencing led to the suppressed tumor growth, plakoglobin translocation and reduced expression of TCF/LEF target genes in tumors.
|
23737966 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of Wnt signaling through beta-catenin/TCF complexes is a key event in the development of various tumors, in particular colorectal and liver tumors.
|
11809809 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It also regulated crucial transcription factors viz. hepatocyte nuclear factor alpha (HNF4A) and tumor suppressor protein 53 (p53).
|
30414976 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In normal cells, E-cadherin exerts its tumour suppressing role mainly by sequestering β-catenin from its binding to LEF (Lymphoid enhancer factor)/TCF (T cell factor) which serves the function of transcribing genes of the proliferative Wnt signaling pathway.
|
29279096 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using an inducible knockout model of the tumor-suppressive isoform of hepatocyte nuclear factor 4 alpha ("P1-HNF4α") in the liver in combination with prolonged high fat (HF) diet, we found that HCC developed equally in male and female mice as early as 38 weeks of age.
|
31575546 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The induction of beta-catenin/TCF mediated transcription is both a frequent early event in colorectal neoplasia, and a key downstream effect of wnt growth factor signalling.
|
16523202 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of these factors, HNF4A acts both as a master regulator of liver organogenesis and a tumor suppressor in the liver.
|
29899848 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that genuine constitutive activation of the TCF/beta-catenin pathway is infrequent in ovarian cancer, but that constitutive transcriptional repression from TCF sites is more common in this tumor type.
|
10739697 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HNF‑4α downregulation promotes tumor migration and invasion by regulating E‑cadherin in renal cell carcinoma.
|
31322246 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data demonstrate that HNF4α does not play a major role during β-catenin-driven HCC, thus revealing that the tumour suppressor role of HNF4α is far more complex and dependent probably on its temporal expression and tumour context.
|
30721564 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High TCF activity Huh7 cells led to earlier and larger tumor formation when xenografted into nude mice.
|
20538055 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The protein expression of the tumor suppressor HNF4α may be inhibited by interactions of RBPs with the G4 motif in the 5' UTR to promote cell proliferation during liver development and carcinogenesis.
|
29234104 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5.
|
23435428 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The P1 and P2 promoter-driven HNF4alpha expression pattern of tumour metastases correlated with the primary site of origin.
|
16400631 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multiple sets of genes and molecular biological processes involved during HCC development were identified from this integrative analysis: (i) Loss of liver cellular features due to the reduced HNF4A & PPAR signaling in the early stages of HCC, (ii) activated inflammatory and stress signals in the cirrhosis stages and (iii) highly activated cellular proliferation with the activated E2F-MYC oncogenic signaling with the gain of embryonic liver stem cell-like features in the advanced stage tumors.
|
27194100 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified a group of CTNNB1/TCF target genes that are activated in the absence of TCF7L1, including EPHB3, a marker of Paneth cell differentiation that has also been implicated as a tumor suppressor in CRC.
|
27333864 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We reveal mechanisms underlying the incompatibility of BMAL1 and P2-HNF4α in HCC, and demonstrate that forced expression of BMAL1 in HNF4α-positive HCC prevents the growth of tumors in vivo.
|
30341289 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, Tcf factors have been reported as tumor inducers, aberrantly activating their target genes as a result of elevated beta-catenin levels in many types of cancer.
|
10528152 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of approximately 450 human colon cancer specimens (Stage III) reveals that P1-HNF4α is either lost or localized in the cytoplasm in approximately 80% of tumors, and that staining for active Src correlates with those events in a subset of samples.
|
22308320 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, nude mice administered MSC-HNF4α exhibited significantly smaller tumors compared with controls in vivo.
|
27124543 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The effect of v-Src was abrogated by a dominant-negative mutant of TCF and the tumor suppressor APC.
|
14706618 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, these data demonstrate the efficacy of disrupting the beta-catenin/TCF transcriptional complex to exploit tumor dependence on Wnt signaling as a therapeutic approach in the treatment of MM.
|
17452641 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The striking suppression effect of HNF4alpha on tumorigenesis and tumor development is attained by inducing the differentiation of hepatoma cells--especially CSCs--into mature hepatocytes, suggesting that differentiation therapy with HNF4alpha may be an effective treatment for HCC patients.
|
18925631 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The abundance and activity of HNF4alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4alpha in renal cells.
|
16007190 |
2005 |